International consensus statement on allergy and rhinology: sinonasal tumors
EC Kuan, EW Wang, ND Adappa… - International forum of …, 2024 - Wiley Online Library
Background Sinonasal neoplasms, whether benign and malignant, pose a significant
challenge to clinicians and represent a model area for multidisciplinary collaboration in …
challenge to clinicians and represent a model area for multidisciplinary collaboration in …
Update from the 5th Edition of the World Health Organization classification of head and neck tumors: nasal cavity, paranasal sinuses and skull base
LDR Thompson, JA Bishop - Head and Neck Pathology, 2022 - Springer
Abstract The World Health Organization Classification of Head and Neck Tumours recently
published the 5th edition. There are new entities, emerging entities, and significant updates …
published the 5th edition. There are new entities, emerging entities, and significant updates …
Phase 1 study of molibresib (GSK525762), a bromodomain and extra-terminal domain protein inhibitor, in NUT carcinoma and other solid tumors
SA Piha-Paul, CL Hann, CA French… - JNCI Cancer …, 2020 - academic.oup.com
Background Bromodomain and extra-terminal domain proteins are promising epigenetic
anticancer drug targets. This first-in-human study evaluated the safety, recommended phase …
anticancer drug targets. This first-in-human study evaluated the safety, recommended phase …
First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours
Background Bromodomain and extra-terminal domain (BET) proteins are reported to be
epigenetic anti-cancer drug targets. This first-in-human study evaluated the safety …
epigenetic anti-cancer drug targets. This first-in-human study evaluated the safety …
BET bromodomain inhibitors: novel design strategies and therapeutic applications
The mammalian bromodomain and extra-terminal domain (BET) family of proteins consists
of four conserved members (Brd2, Brd3, Brd4, and Brdt) that regulate numerous cancer …
of four conserved members (Brd2, Brd3, Brd4, and Brdt) that regulate numerous cancer …
Supercharging BRD4 with NUT in carcinoma
KP Eagen, CA French - Oncogene, 2021 - nature.com
NUT carcinoma (NC) is an extremely aggressive squamous cancer with no effective therapy.
NC is driven, most commonly, by the BRD4-NUT fusion oncoprotein. BRD4-NUT combines …
NC is driven, most commonly, by the BRD4-NUT fusion oncoprotein. BRD4-NUT combines …
Report of the first international symposium on NUT carcinoma
NUT carcinoma is a rare, aggressive cancer defined by rearrangements of the NUTM1 gene.
No routinely effective treatments of NUT carcinoma exist, despite harboring a targetable …
No routinely effective treatments of NUT carcinoma exist, despite harboring a targetable …
The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors
Abstract NSD1, NSD2, and NSD3 constitute the nuclear receptor-binding SET Domain
(NSD) family of histone 3 lysine 36 (H3K36) methyltransferases. These structurally similar …
(NSD) family of histone 3 lysine 36 (H3K36) methyltransferases. These structurally similar …
A NSD3-targeted PROTAC suppresses NSD3 and cMyc oncogenic nodes in cancer cells
Nuclear receptor binding SET domain protein 3 (NSD3), a gene located within the 8p11-p12
amplicon frequently detected in human cancers, encodes a chromatin modulator and an …
amplicon frequently detected in human cancers, encodes a chromatin modulator and an …
Combined targeting of the BRD4–NUT–p300 axis in NUT midline carcinoma by dual selective bromodomain inhibitor, NEO2734
CD Morrison-Smith, TM Knox, I Filic, KM Soroko… - Molecular cancer …, 2020 - AACR
NUT midline carcinoma (NMC) is a rare, aggressive subtype of squamous carcinoma that is
driven by the BRD4-NUT fusion oncoprotein. BRD4, a BET protein, binds to chromatin …
driven by the BRD4-NUT fusion oncoprotein. BRD4, a BET protein, binds to chromatin …